

主要学会 前立腺癌関連演題一覧

ASCO-GU 2019 前立腺癌関連重要演題一覧

本年も ASCO-GU 2019 では非常に多くの前立腺癌関連の発表がなされたが、今回はそのなかから本誌編集主幹・委員 4 名により特に重要な演題を選出し、掲載する。

なお、すべての前立腺癌関連演題の一覧は、右の QR コードもしくは下記の URL からアクセス可能なので、是非ご参照いただきたい。

https://med.m-review.co.jp/espoir_detail?id=1&convention_id=1

※ Abstract No の下の★の数は、4 名の本誌編集主幹・委員のうちその演題を重要演題として選出した人数を表している。



Abstract No	Title	1st Author
▶1★	PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).	Nicholas John Van As
▶15★	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.	Jeremie Calais
▶19★	Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?	Marc Dall'era
▶20★★	Outcomes of the patients with pT0 on first protocol biopsy during active surveillance for early prostate cancer: From the PRIAS-JAPAN study.	Takuma Kato
▶42★	Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.	Felix Y Feng
▶46★	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.	Harry Brastianos
▶71★	Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.	Ricardo Pereira Mestre
▶98★	Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.	Jaime Omar Herrera-Caceres
▶139★	Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).	Silke Gillissen
▶140★★★★	ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).	Karim Fizazi
▶141★★★★	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCRPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).	Karim Fizazi
▶142★★	Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).	Padmanee Sharma
▶143★★	Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.	Howard I. Scher
▶144★★★★	Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).	Eric Jay Small
▶145★★★★	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).	Evan Y. Yu
▶154★★	Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.	Catherine Handy Marshall
▶164★★	A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases.	Hiroji Uemura
▶170★★	Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) -pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).	Christophe Massard
▶171★★	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi) -pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).	Peter C.C. Fong